Myelofibrosis

Jakafi® for Intermediate or High-risk Myelofibrosis


What is Jakafi?

Jakafi (JAK-ah-fye) is a prescription medicine available as a pill. Jakafi is used to treat people with intermediate or high-risk myelofibrosis (MF).

Jakafi is the first and only medicine approved by the Food and Drug Administration (FDA) for the treatment of these patients.

Jakafi is not chemotherapy. It is a targeted treatment that works to help keep the production of blood cells under control.



Is your MF considered intermediate or high-risk?

Find out how your MF risk level is determined and whether or not Jakafi may be a possible treatment option for you.


How does Jakafi work?

MF is a complex condition and researchers are still trying to discover its exact cause. Evidence suggests that proteins known as Janus kinases, or JAKs, are involved. JAK proteins send signals that affect the production of blood cells in the bone marrow (A). When JAKs send too many signals, they cause the body to make the wrong number of blood cells. This chain of events is called overactive JAK signaling (B).

JAK signaling may become overactive in many ways. One way is by a JAK mutation. A mutation is a small change in the DNA that causes proteins to act differently than normally intended. All people with MF are believed to have overactive JAK signaling even if they do not have a JAK mutation.

Jakafi works by targeting JAKs, which control the production of blood cells. In doing so, Jakafi helps to reduce overactive JAK signaling to help keep the production of blood cells under
control (C).


What are possible side effects of Jakafi?

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your Healthcare Professional. Your Healthcare Professional will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your Healthcare Professional may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your Healthcare Professional right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your Healthcare Professional if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your Healthcare Professional if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your Healthcare Professional will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: low platelet count, low red blood cell counts, bruising, dizziness, headache.

These are not all the possible side effects of Jakafi. Ask your pharmacist or Healthcare Professional for more information. Tell your Healthcare Professional about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your Healthcare Professional about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, had skin cancer, or have any other medical condition. Take Jakafi exactly as your Healthcare Professional tells you. Do not change your dose or stop taking Jakafi without first talking to your Healthcare Professional. Do not drink grapefruit juice while on Jakafi.

Women should not take Jakafi while pregnant or planning to become pregnant, or if breast-feeding.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

Image of Sue – Watch her story and learn how her MF symptoms affected her before she started taking Jakafi.

Learn how the symptoms of MF affected Sue before she started taking Jakafi

Discover how Sue’s MF symptoms prompted her to talk to her Healthcare Professional about moving her treatment journey forward with Jakafi.

Watch Sue’s Story
Image of woman – Jakafi patient – talking on the phone, sitting on a park bench

Talk with a patient taking Jakafi

Register for the Incyte Mentor Program and connect with another patient taking Jakafi.

Learn How
connect-patient

Connect With a Patient Like Sue

Connect With a
Patient Like Sue

Register for the Incyte Mentor Program and connect with another patient taking Jakafi.

Email Address

Continue Registering

Expand Collapse

Important Safety Information

Indications and Usage

Jakafi is a prescription medicine used to treat people with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is also used to treat certain types of myelofibrosis.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: low platelet count, low red blood cell counts, bruising, dizziness, headache.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider. Do not drink grapefruit juice while on Jakafi.

Women should not take Jakafi while pregnant or planning to become pregnant, or if breast-feeding.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.